Skip to content
ClinCalc Pro
Menu
Antiarrhythmic (Purinergic)

Adenosine

Brand names: Adenocor

Adenosine is an endogenous purine nucleoside given as a rapid intravenous bolus to terminate paroxysmal supraventricular tachycardia and to aid diagnosis of broad- or narrow-complex tachycardias.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Acting on A1 receptors it transiently slows conduction through the atrioventricular node, interrupting re-entry circuits that depend on the AV node and restoring sinus rhythm.

Prescribing in practice

  • It can cause transient asystole, profound bradycardia, and bronchospasm, so it must be given with continuous ECG and resuscitation facilities and used cautiously or avoided in asthma.
  • Because its half-life is extremely short it must be given as a rapid bolus into a large proximal vein followed by an immediate saline flush.
  • Effect is potentiated by dipyridamole and antagonised by caffeine and theophylline, and it should be avoided in second- or third-degree heart block without a pacemaker.

Monitoring

Record continuous ECG during administration to capture the rhythm response and to detect transient pauses, AV block, or new arrhythmia.

Counselling the patient

  • Warn the patient they may briefly feel flushing, chest tightness, or a sense of impending doom that passes within seconds.
  • Reassure that these effects are short-lived because the drug is broken down very quickly.
  • Explain the heart rhythm is being recorded throughout to guide treatment.

Evidence & guidelines

Adenosine is the first-line agent for terminating AV-nodal-dependent supraventricular tachycardia in UK and Resuscitation Council tachycardia algorithms.

Reference: Resuscitation Council UK ACLS Guidelines 2021; ESC SVT Guidelines 2019; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.